Combination therapies in prostate cancer: proceed with caution

This publication has 9 references indexed in Scilit:

• Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet Oncology, 2019
• Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
  European Urology, 2018
• Vertebral Compression Fracture After Spine Stereotactic Body Radiation Therapy: A Review of the Pathophysiology and Risk Factors
  Neurosurgery, 2017
• Differences in responses to X-ray exposure between osteoclast and osteoblast cells
  Journal of Radiation Research, 2017
• Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
  The Lancet Oncology, 2016
• Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
  Cancer Research, 2015
• Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
  The Lancet Oncology, 2012
• Effects of Low-Dose Prednisone on Bone Metabolism
  Journal of Bone and Mineral Research, 2005
• Identification of androgen receptors in normal human osteoblast-like cells.
  Proceedings of the National Academy of Sciences, 1989